Posts Tagged ‘CRIS’

CRIS soars, C active, S slips

Monday, March 21st, 2011

Curis Inc. (Nasdaq: CRIS) shares climbed 14% to $3.34, on three million shares, or five times its daily average, after the drug developer and its partner Roche Group announced positive results from a midstage study of their skin-cancer treatment.

Citigroup Inc. (NYSE: C) traded in 263 million shares Monday, closing in on a daily average of 482 million. C announced Monday it will slash the number of common shares outstanding through a 1-for-10 reverse stock split, and reintroduce a dividend

Sprint Nextel Corp. (NYSE: S) shares declined 13.4% to $4.38, on volume of 134 million shares, better than double its daily average of 55 million, a trading day after rival AT&T Inc. (NYSE: T) said it would acquire T-Mobile USA from Deutsche Telekom AG in a $39-billion deal that would make AT&T the largest U.S. wireless carrier.

CRIS incredible, MU moves shares, THOR loses ground

Wednesday, January 12th, 2011

Curis Inc. (Nasdaq: CRIS) shares gained 20.2% to $2.74 Wednesday. Volume of 1,361,514 proved four times its full-day average. The Mass.-based CRIS is a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment.

Micron Technology Inc. (Nasdaq: MU) traded in 53,997,533 shares Wednesday, nearly doubling its daily average of 30,541,700. Prices for MU were up 7.1 to $9.34.

Thoratec Corporatino (Nasdaq: THOR) fell 7.4 percent Wednesday to $28.81. Volume for the stock was 4,263,232 shares or three times its daily average. THOR is a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts.